The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
Open accessAbstract
PURPOSE: To update recommendations on appropriate use of breast cancer biomarker assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast cancer. METHODS: An updated literature search identified randomized clinical trials and prospective-retrospective studies published from January 2016 to October 2021. Outcomes of interest included overall survival and disease-free or recurrence-free survival. Expert Panel members used informal consensus to develop evidence-based recommendations. RESULTS: The search identified 24 studies informing the evidence base. RECOMMENDATIONS: Clinicians may use Onco type DX, MammaPrint, Breast Cancer Index (BCI), and EndoPredict to guide adjuvant endocrine and chemotherapy in patients who are postmenopausal or age > 50 years with early-stage estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative (ER+ and HER2–) breast cancer that is node-negative or with 1-3 positive nodes. Prosigna and BCI may be used in postmenopausal patients with node-negative ER+ and HER2– breast cancer. In premenopausal patients, clinicians may use Onco type in patients with node-negative ER+ and HER2– breast cancer. Current data suggest that premenopausal patients with 1-3 positive nodes benefit from chemotherapy regardless of genomic assay result. There are no data on use of genomic tests to guide adjuvant chemotherapy in patients with ≥ 4 positive nodes. Ki67 combined with other parameters or immunohistochemistry 4 score may be used in postmenopausal patients without access to genomic tests to guide adjuvant therapy decisions. BCI may be offered to patients with 0-3 positive nodes who received 5 years of endocrine therapy without evidence of recurrence to guide decisions about extended endocrine therapy. None of the assays are recommended for treatment guidance in individuals with HER2-positive or triple-negative breast cancer. Treatment decisions should also consider disease stage, comorbidities, and patient preferences. Additional information is available at www.asco.org/breast-cancer-guidelines .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270 · cited 1×
“However, larger randomized studies have suggested that an increase in pathologic response rate with the addition of preoperative PD-1 or PD-L1 inhibition appears independent of tumor PD-L1 status.(67,68) It is not known if PD-L1 tumor status will predict any survival benefit from the addition of an immune-oncology dru…”
BackgroundAdjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397
Ferrell, B. R., Temel, J. S., Temin, S., Alesi, E. R., Balboni, T. A., Basch, E. M., Firn, J. I., Paice, J. A., Peppercorn, J. M., Phillips, T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1474 · Cited by 2,117
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Cardoso, F., van’t Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., Pierga, J.-Y., Brain, E., Causeret, S., DeLorenzi, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602253 · Cited by 1,994
Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,762
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., Rouas, G., Francis, P., Crown, J. P. A., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,632
Adams, S., Gray, R. J., Demaria, S., Goldstein, L., Perez, E. A., Shulman, L. N., Martino, S., Wang, M., Jones, V. E., Saphner, T. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0491 · Cited by 1,299
Self-citationLoi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., Kellokumpu-Lehtinen, P.-L., Bono, P., Kataja, V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,256
Denkert, C., von Minckwitz, G., Brase, J. C., Sinn, B. V., Gade, S., Kronenwett, R., Pfitzner, B. M., Salat, C., Loi, S., Schmitt, W. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1967 · Cited by 1,026
Merker, J. D., Oxnard, G. R., Compton, C., Diehn, M., Hurley, P., Lazar, A. J., Lindeman, N., Lockwood, C. M., Rai, A. J., Schilsky, R. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8671 · Cited by 959
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Tyne, C., Blayney, D. W., Blum, D., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6706 · Cited by 912
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Kalinsky, K., Barlow, W. E., Gralow, J. R., Meric-Bernstam, F., Albain, K. S., Hayes, D. F., Lin, N. U., Perez, E. A., Goldstein, L. J., Chia, S. K. L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108873 · Cited by 870
Self-citationHarris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., Hammond, E. H., Kuderer, N. M., Liu, M. C., Mennel, R. G., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.2289 · Cited by 811
Self-citationNielsen, T. O., Leung, S. C. Y., Rimm, D. L., Dodson, A., Acs, B., Badve, S., Denkert, C., Ellis, M. J., Fineberg, S., Flowers, M., et al. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djaa201 · Cited by 753
Cuzick, J., Dowsett, M., Pineda, S., Wale, C., Salter, J., Quinn, E., Zabaglo, L., Mallon, E., Green, A. R., Ellis, I. O., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2835 · Cited by 739
Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B. V., Blohmer, J.-U., Grischke, E.-M., Furlanetto, J., Tesch, H., Hanusch, C., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz158 · Cited by 695
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Blayney, D. W., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., Lyman, G. H., Meropol, N. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2518 · Cited by 655
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Meropol, N. J., Schrag, D., Smith, T. J., Mulvey, T. M., Langdon, R. M., Blum, D., Ubel, P. A., & Schnipper, L. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1183 · Cited by 638
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
Rack, B., Schindlbeck, C., Jückstock, J., Andergassen, U., Hepp, P., Zwingers, T., Friedl, T. W. P., Lorenz, R., Tesch, H., Fasching, P. A., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju066 · Cited by 615 · cited 2×
“Surveillance-Trial (SUCCESS) using the CellSearch System.(69) The SUCCESS investigators compared fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel versus fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel plus gemcitabine, and 2 versus 5 years of treatment with zoledronic acid in 3…”
MethodPatient-clinician communication: American Society of Clinical Oncology consensus guideline
Gilligan, T., Coyle, N., Frankel, R. M., Berry, D. L., Bohlke, K., Epstein, R. M., Finlay, E., Jackson, V. A., Lathan, C. S., Loprinzi, C. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2311 · Cited by 610
Salgado, R., Denkert, C., Campbell, C., Savas, P., Nuciforo, P., Aura, C., de Azambuja, E., Eidtmann, H., Ellis, C. E., Baselga, J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0830 · Cited by 605
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Sparano, J. A., Gray, R. J., Ravdin, P. M., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904819 · Cited by 532
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence
Coombes, R. C., Page, K., Salari, R., Hastings, R. K., Armstrong, A., Ahmed, S., Ali, S., Cleator, S., Kenny, L., Stebbing, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3663 · Cited by 510
Circulating tumour cells in non-metastatic breast cancer: a prospective study
Lucci, A., Hall, C. S., Lodhi, A. K., Bhattacharyya, A., Anderson, A. E., Xiao, L., Bedrosian, I., Kuerer, H. M., & Krishnamurthy, S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70209-7 · Cited by 507
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Dusetzina, S. B., Winn, A. N., Abel, G. A., Huskamp, H. A., & Keating, N. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9123 · Cited by 500
Dieci, M. V., Criscitiello, C., Goubar, A., Viale, G., Conte, P., Guarneri, V., Ficarra, G., Mathieu, M. C., Delaloge, S., Curigliano, G., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt556 · Cited by 460
Self-citationOlsson, E., Winter, C., George, A., Chen, Y., Howlin, J., Tang, M. E., Dahlgren, M., Schulz, R., Grabau, D., van Westen, D., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404913 · Cited by 453
Dieci, M. V., Radosevic-Robin, N., Fineberg, S., van den Eynden, G., Ternes, N., Penault-Llorca, F., Pruneri, G., D’Alfonso, T. M., Demaria, S., Castaneda, C., et al. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.003 · Cited by 433
Schmid, P., Salgado, R., Park, Y. H., Muñoz-Couselo, E., Kim, S. B., Sohn, J., Im, S.-A., Foukakis, T., Kuemmel, S., Dent, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.072 · Cited by 413
Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer
Garcia-Murillas, I., Chopra, N., Comino-Méndez, I., Beaney, M., Tovey, H., Cutts, R. J., Swift, C., Kriplani, D., Afentakis, M., Hrebien, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1838 · Cited by 410
Van Poznak, C., Somerfield, M. R., Bast, R. C., Cristofanilli, M., Goetz, M. P., Gonzalez-Angulo, A. M., Hicks, D. G., Hill, E. G., Liu, M. C., Lucas, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.1459 · Cited by 404
Sgroi, D. C., Sestak, I., Cuzick, J., Zhang, Y., Schnabel, C. A., Schroeder, B., Erlander, M. G., Dunbier, A., Sidhu, K., Lopez-Knowles, E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70387-5 · Cited by 399
Wimberly, H., Brown, J. R., Schalper, K., Haack, H., Silver, M. R., Nixon, C., Bossuyt, V., Pusztai, L., Lannin, D. R., & Rimm, D. L. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0133 · Cited by 397
Self-citationHarbeck, N., Rastogi, P., Martin, M., Tolaney, S. M., Shao, Z. M., Fasching, P. A., Huang, C. S., Jaliffe, G. G., Tryakin, A., Goetz, M. P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.015 · Cited by 381
Piccart, M., van 't Veer, L. J., Poncet, C., Lopes Cardozo, J. M. N., Delaloge, S., Pierga, J.-Y., Vuylsteke, P., Brain, E., Vrijaldenhoven, S., Neijenhuis, P. A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00007-3 · Cited by 369
Gluz, O., Nitz, U. A., Christgen, M., Kates, R. E., Shak, S., Clemens, M., Kraemer, S., Aktas, B., Kuemmel, S., Reimer, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5383 · Cited by 333
Sestak, I., Buus, R., Cuzick, J., Dubsky, P., Kronenwett, R., Denkert, C., Ferree, S., Sgroi, D., Schnabel, C., Baehner, F. L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5524 · Cited by 318
Krop, I., Ismaila, N., Andre, F., Bast, R. C., Barlow, W., Collyar, D. E., Hammond, M. E., Kuderer, N. M., Liu, M. C., Mennel, R. G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.0472 · Cited by 315
Self-citationRadovich, M., Jiang, G., Hancock, B. A., Chitambar, C., Nanda, R., Falkson, C., Lynce, F. C., Gallagher, C., Isaacs, C., Blaya, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2295 · Cited by 307
Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
Streeter, S. B., Schwartzberg, L., Husain, N., & Johnsrud, M. (2011) · Journal of Oncology Practice · doi:10.1200/jop.2011.000316 · Cited by 248
Andre, F., Ismaila, N., Henry, N. L., Somerfield, M. R., Bast, R. C., Barlow, W., Collyar, D. E., Hammond, M. E., Kuderer, N. M., Liu, M. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00945 · Cited by 230
Self-citationIssa-Nummer, Y., Darb-Esfahani, S., Loibl, S., Kunz, G., Nekljudova, V., Schrader, I., Sinn, B. V., Ulmer, H.-U., Kronenwett, R., Just, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079775 · Cited by 224
Sparano, J., O’Neill, A., Alpaugh, K., Wolff, A. C., Northfelt, D. W., Dang, C. T., Sledge, G. W., & Miller, K. D. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2574 · Cited by 203
Self-citationBartlett, J. M. S., Sgroi, D. C., Treuner, K., Zhang, Y., Ahmed, I., Piper, T., Salunga, R., Brachtel, E. F., Pirrie, S. J., Schnabel, C. A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz289 · Cited by 203
Blok, E. J., Kroep, J. R., Meershoek-Klein Kranenbarg, E., Duijm-de Carpentier, M., Putter, H., van den Bosch, J., Maartense, E., van Leeuwen-Stok, A. E., Liefers, G.-J., Nortier, J. W. R., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx134 · Cited by 200
Luen, S. J., Salgado, R., Dieci, M. V., Vingiani, A., Curigliano, G., Gould, R. E., Castaneda, C., D’Alfonso, T., Sanchez, J., Cheng, E., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy547 · Cited by 198
Dowsett, M., Sestak, I., Regan, M. M., Dodson, A., Viale, G., Thürlimann, B., Colleoni, M., & Cuzick, J. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.4258 · Cited by 193
Nitz, U., Gluz, O., Christgen, M., Kates, R. E., Clemens, M., Malter, W., Nuding, B., Aktas, B., Kuemmel, S., Reimer, T., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4358-6 · Cited by 189
Shiffman, R. N., Michel, G., Rosenfeld, R. M., & Davidson, C. (2012) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000172 · Cited by 184
Lænkholm, A.-V., Jensen, M.-B., Eriksen, J. O., Rasmussen, B. B., Knoop, A. S., Buckingham, W., Ferree, S., Schaper, C., Nielsen, T. O., Haffner, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.6586 · Cited by 176
Sparano, J. A., Gray, R. J., Makower, D. F., Albain, K. S., Saphner, T. J., Badve, S. S., Wagner, L. I., Kaklamani, V. G., Keane, M. M., Gomez, H. L., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.4794 · Cited by 166
Martin, M., Brase, J. C., Calvo, L., Krappmann, K., Ruiz-Borrego, M., Fisch, K., Ruiz, A., Weber, K. E., Munarriz, B., Petry, C., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3642 · Cited by 163
Sparano, J. A., Crager, M., Tang, G., Gray, R. J., Stemmer, S. M., & Shak, S. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.03007 · Cited by 154
Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis
Trapp, E. K., Janni, W., Schindlbeck, C., Jückstöck, J., Andergassen, U., de Gregorio, A., Alunni‐Fabbroni, M., Tzschaschel, M. L. J., Polasik, A., Koch, J., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy152 · Cited by 149
Noordhoek, I., Treuner, K., Putter, H., Zhang, Y., Wong, J., Kranenbarg, E. M., Carpentier, M. D., van de Velde, C. J. �., Schnabel, C. A., & Liefers, G. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2737 · Cited by 142
Pruneri, G., Gray, K. P., Vingiani, A., Viale, G., Curigliano, G., Criscitiello, C., Láng, I., Ruhstaller, T., Gianni, L., Goldhirsch, A., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3863-3 · Cited by 129
Ohnstad, H. O., Borgen, E., Falk, R. S., Lien, T. G., Aaserud, M., Sveli, M., Kyte, J. A., Kristensen, V. N., Geitvik, G. A., Schlichting, E., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0911-9 · Cited by 126
Albain, K. S., Gray, R. J., Makower, D., Faghih, A., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., Lively, T., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa148 · Cited by 123
Dieci, M. V., Conte, P., Bisagni, G., Brandes, A. A., Frassoldati, A., Cavanna, L., Musolino, A., Giotta, F., Rimanti, A., Garrone, O., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz007 · Cited by 95
Šestak, I., Martín, M., Dubsky, P. C., Kronenwett, R., Rojo, F., Cuzick, J. M., Filipits, M., Ruı́z, A., Gradishar, W. J., Soliman, H. H., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05226-8 · Cited by 95
Wang, S., Dang, W., Richman, I. B., Mougalian, S. S., Evans, S. B., & Gross, C. P. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.5941 · Cited by 89
Sgroi, D. C., Chapman, J.-A. W., Badovinac-Črnjević, T., Zarrella, E., Binns, S., Zhang, Y., Schnabel, C. A., Erlander, M. G., Pritchard, K. I., Han, L., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0660-6 · Cited by 73
Poorvu, P. D., Gelber, S. I., Rosenberg, S. M., Ruddy, K. J., Tamimi, R. M., Collins, L. C., Peppercorn, J. M., Schapira, L., Borges, V. F., Come, S. E., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01959 · Cited by 73
Noordhoek, I., Blok, E. J., Kranenbarg, E. M., Putter, H., Carpentier, M. D., Rutgers, E. J. T., Seynaeve, C., Bartlett, J. M. S., Vannetzel, J.-M., Rea, D. W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02427 · Cited by 40
Šestak, I., Filipits, M., Buus, R., Rudas, M., Balić, M., Knauer, M., Kronenwett, R., Fitzal, F., Cuzick, J. M., Gnant, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0260 · Cited by 39
Kolberg-Liedtke, C., Gluz, O., Heinisch, F., Feuerhake, F., Kreipe, H. H., Clemens, M., Nuding, B., Malter, W., Reimer, T., Wuerstlein, R., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01283-w · Cited by 37
Circulating tumor cells in non-metastatic triple-negative breast cancer
Karhade, M., Hall, C. S., Mishra, P., Anderson, A. E., Kuerer, H. M., Bedrosian, I., Krishnamurthy, S., & Lucci, A. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3103-7 · Cited by 36
Magbanua, M. J. M., Yau, C. S. F., Wolf, D. M., Lee, J. S., Chattopadhyay, A., Scott, J. H., Bowlby-Yoder, E., Hwang, E. S., Alvarado, M. D., Ewing, C. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3888 · Cited by 36
Jensen, M., Lænkholm, A., Balslev, E., Buckingham, W., Ferree, S., Glavicic, V., Jensen, J. D., Knoop, A. S., Mouridsen, H. T., Nielsen, D. L., et al. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-0148-0 · Cited by 32
Wang, C., Chen, C., Lin, Y., Zhou, Y., Mao, F., Zhu, H., Zhang, X., Shen, S., Huang, X., Wang, X., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-61648-1 · Cited by 21
Hepp, P. G., Andergassen, U., Jäger, B., Trapp, E. K., Alunni‐Fabbroni, M., Friedl, T. W. P., HECKER, N., Lorenz, R., Fasching, P. A., Schneeweiß, A., et al. (2016) · Anticancer Research · doi:10.21873/anticanres.11034 · Cited by 14
Ettl, J., Anders, S.-I., Hapfelmeier, A., Paepke, S., Noske, A., Weichert, W., Klein, E., & Kiechle, M. B. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05771-4 · Cited by 13
Cited by
Deciphering breast cancer: from biology to the clinic
Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023) · Cell · doi:10.1016/j.cell.2023.01.040 · Cited by 730
Breast cancer: an up‐to‐date review and future perspectives
Hong, R., & Xu, B. (2022) · Cancer Communications · doi:10.1002/cac2.12358 · Cited by 407
Shamai, G., Cohen, S., Binenbaum, Y., Sabo, E., Cretu, A., Mayer, C., Barshack, I., Goldman, T., Bar-Sela, G., Polónia, A., et al. (2025) · doi:10.1101/2025.05.15.25327686 · Cited by 3
Metadata
- Authors
- Andre, F., Ismaila, N., Allison, K. H., Barlow, W. E., Collyar, D. E., Damodaran, S., Henry, N. L., Jhaveri, K., Kalinsky, K., Kuderer, N. M., Litvak, A., Mayer, E. L., Pusztai, L., Raab, R., Wolff, A. C., & Stearns, V.
- Venue
- Journal of Clinical Oncology
- Published
- 2022-06-01
- Volume
- 40
- Issue
- 16
- Pages
- 1816-1837
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4224213278
- Cited by
- 365
- References
- 72
- FWCI
- 24.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.